Verpora and Manatt Health — joined by a US payer voice for the first time — share insights to help manufacturers prepare for IPAY 2028, including early strategy, Part B inclusion, and evolving CMS negotiation dynamics.

In this final episode of the series, Omar Ali speaks with Dr Abdulrazag Al-Jazairi about Saudi Arabia’s evolving HTA landscape, the influence of international frameworks, and the country’s growing use of value-based agreements in pricing strategy.

Omar Ali is joined by Professor Lieven Annemans to unpack the tensions between EU-wide harmonisation and local relevance in HTA. From JCA readiness to the risks of over-assessment, they explore how well-intentioned policy can drift from its original purpose.

Omar Ali speaks with Canadian health economist Don Husereau about the tension between policy idealism and real-world pragmatism in Canada’s decentralised pricing and HTA landscape.

Omar Ali and Dr Krzysztof Łanda unpack HTA reform, MFN pressures, and Poland’s evolving pricing system shaped by politics, economics, and EU shifts.

Omar Ali and Dr Yousaf Ahmad discuss NHS pricing pressures, VBAs in practice, and how UK access is adapting to MFN and oncology complexities.

In this focused 60-minute session, Verpora INSPIRE! leaders explore how international teams are adapting to rising pricing pressure, leaner resources, and increased payer scrutiny.

Can innovative contracts keep pace with curative therapies? Hemgenix’s 10-year deal in Europe might be the future. This episode unpacks how and why it worked.

Value alignment is especially difficult in rare diseases. In this Fireside Chat, we explore why and how manufacturers can create space for productive negotiation.

Payers and manufacturers often see evidence differently. This episode explores why value mismatches happen and how pharma can bridge the gap.

Spanish payer Jaime Espín joins Omar Ali to discuss regulatory reform, transparency in pricing, and the evolving use of outcome-based payment models in Spain’s healthcare system.

Dutch HTA expert Hans Severens speaks with Omar Ali about value-based pricing, disease severity as a modifier, and the challenges of system sustainability in the Netherlands.

Italian AIFA member Fabrizio Gianfrate joins Omar Ali to discuss rare disease pricing, payment-over-time challenges, and the realities of reimbursement in the Italian healthcare system.

German payer Detlev Parow joins Verpora’s Omar Ali to discuss obesity, indication-based pricing, and risk-sharing models for gene therapies in one of Europe’s most complex healthcare systems.

Former CEPS member Jean-Claude Castanier joins Verpora’s Omar Ali to discuss France’s approach to multi-indication pricing, transparency, and long-term healthcare system sustainability.

Through the eyes of Omar Ali - a former NICE insider; a 30,000-foot full-throttle take on the collapse of NHS England's structure – and the ripple effects across commissioning, VPAG, NICE, ICBs and pharma's next move.

Unlike cheap oral drugs, early PCSK9s were high-cost injections — and a tough sell. But one manufacturer used a VBA to secure trust and gain early access.

Why do innovative contracts fail? Omar Ali and Adam Buckler explore real-world VBAs that didn’t launch—and what those failures teach us about doing it right.

Physician buy-in can make or break an innovative contract. In this episode, we explore real-world strategies to engage prescribers, overcome resistance, and drive adoption.

A bold performance-based contract looked like a win—until a key stakeholder pushed back. In this episode, we explore why stakeholder engagement is critical in Innovative Contracting. in cell and gene therapy.